168 related articles for article (PubMed ID: 23956056)
21. Has‑miR‑125a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53‑dependent manner by targeting p53 mRNA.
Chen JJ; Liu SX; Chen MZ; Zhao ZY
Mol Med Rep; 2015 Sep; 12(3):3569-3574. PubMed ID: 26017674
[TBL] [Abstract][Full Text] [Related]
22. Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells.
Zeng Q; Wang Z; Liu C; Gong Z; Yang L; Jiang L; Ma Z; Qian Y; Yang Y; Kang H; Hong S; Bu Y; Hu G
Mol Cell Biochem; 2016 Jul; 418(1-2):137-46. PubMed ID: 27334757
[TBL] [Abstract][Full Text] [Related]
23. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.
Nakahara S; Hanamoto A; Seo Y; Miyaguchi S; Yamamoto Y; Tomiyama Y; Yoshii T; Takenaka Y; Yoshioka Y; Isohashi F; Ogawa K; Inohara H
Jpn J Clin Oncol; 2016 Oct; 46(10):903-910. PubMed ID: 27474126
[TBL] [Abstract][Full Text] [Related]
24. CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma.
Liu Z; Cheng C; Luo X; Xia Q; Zhang Y; Long X; Jiang Q; Fang W
BMC Cancer; 2016 Mar; 16():238. PubMed ID: 26993269
[TBL] [Abstract][Full Text] [Related]
25. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
[TBL] [Abstract][Full Text] [Related]
26. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
27. EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene.
Huang Y; Wang X; Niu X; Wang X; Jiang R; Xu T; Liu Y; Liang L; Ou X; Xing X; Li W; Hu C
Mol Carcinog; 2017 Feb; 56(2):447-463. PubMed ID: 27253463
[TBL] [Abstract][Full Text] [Related]
28. Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma.
Yoshizaki T; Kondo S; Murono S; Endo K; Tsuji A; Nakanishi Y; Nakanishi S; Sugimoto H; Hatano M; Ueno T; Wakisaka N
Jpn J Clin Oncol; 2015 Mar; 45(3):244-7. PubMed ID: 25583421
[TBL] [Abstract][Full Text] [Related]
29. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
[TBL] [Abstract][Full Text] [Related]
30. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
31. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
[TBL] [Abstract][Full Text] [Related]
32. miR-1278 sensitizes nasopharyngeal carcinoma cells to cisplatin and suppresses autophagy via targeting ATG2B.
Zhao Y; Wang P; Wu Q
Mol Cell Probes; 2020 Oct; 53():101597. PubMed ID: 32407879
[TBL] [Abstract][Full Text] [Related]
33. [miR-129-1-3p reverses cisplatin resistance of HNE1/CDDP human nasopharyngeal carcinoma cells by targeting inhibition of WEE1 kinase].
Zhang H; Lu J; Jiang C; Lu W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Nov; 35(11):1014-1019. PubMed ID: 31878998
[TBL] [Abstract][Full Text] [Related]
34. Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases.
Zhou Z; Meng M; Ni H
Med Sci Monit; 2017 Jan; 23():462-469. PubMed ID: 28124680
[TBL] [Abstract][Full Text] [Related]
35. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
36. BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma.
Gao W; Li JZ; Chen SQ; Chu CY; Chan JY; Wong TS
Cancer Med; 2017 Feb; 6(2):439-451. PubMed ID: 28083995
[TBL] [Abstract][Full Text] [Related]
37. O(6) -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma.
Chen SH; Kuo CC; Li CF; Cheung CH; Tsou TC; Chiang HC; Yang YN; Chang SL; Lin LC; Pan HY; Chang KY; Chang JY
Int J Cancer; 2015 Sep; 137(6):1291-305. PubMed ID: 25693518
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of GRP78 enhances cell death by cisplatin and radiotherapy in nasopharyngeal cells.
Huang YY; Pu LJ; Song LL; Ma LY; Liu H; Jiang CC
Anticancer Drugs; 2016 Sep; 27(8):726-33. PubMed ID: 27254284
[TBL] [Abstract][Full Text] [Related]
39. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
40. ARC is highly expressed in nasopharyngeal carcinoma and confers X-radiation and cisplatin resistance.
Wu P; Tang Y; He J; Qi L; Jiang W; Zhao S
Oncol Rep; 2013 Oct; 30(4):1807-13. PubMed ID: 23877130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
